Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Heart failure related to PAH is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue.

Dr Ahmed Fahim discusses the UK Idiopathic Pulmonary Fibrosis Registry and how its findings enhance understanding and ...

A board certified cardiologist has shared a list of the seven most common signs and symptoms to look out for as it could mean ...

Pulmonary artery denervation (PADN) may help lower high blood pressure in pulmonary hypertension, a meta-analysis of studies ...

Pulmonologists share best practices on when primary care providers should consider sending patients with respiratory ...

Report Ocean’s latest analysis delves into the “Vietnam Pulmonary Arterial Hypertension Market” Report from 2024 to 2032, covering an array of market facets such as characteristics, size, growth, ...

Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) 74th Annual Scientific Session and Expo in Chicago, March 29-31.

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.